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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Recent studies using small bowel endoscopy revealed that non 
steroidal anti inflammatory drugs including low dose aspirin, can
often induce small bowel injury. Non steroidal anti inflammatory
drugs induced small bowel mucosal injury involves various factors
such as enterobacteria, cytokines, and bile. Experimental studies
demonstrate that both mitochondrial disorders and inhibition of
cyclooxygenases are required for development of non steroidal
anti inflammatory drugs induced small bowel injury. Mitochondrion
is an organelle playing a central role in energy production in
organisms. Many non steroidal anti inflammatory drugs directly
cause mitochondrial disorders, which are attributable to uncoupling
of oxidative phosphorylation induced by opening of the mega
channel called mitochondrial permeability transition pore on the
mitochondrial membrane by non steroidal anti inflammatory
drugs. Bile acids and tumor necrosis factor α also can open the
permeability transition pore. The permeability transition pore
opening induces the release of cytochrome c from mitochondrial
matrix into the cytosol, which triggers a cascade of events that
will lead to cell death. Therefore these mitochondrial disorders
may cause disturbance of the mucosal barrier function and eleva 
tion of the small bowel permeability, and play particularly impor 
tant roles in early processes of non steroidal anti inflammatory
drugs induced small bowel injury. Although no valid means of
preventing or treating non steroidal anti inflammatory drugs 
induced small bowel injury has been established, advances in
mitochondrial studies may bring about innovation in the preven 
tion and treatment of this kind of injury.
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Introduction It has been known since many years ago that non-steroidal
anti-inflammatory drugs (NSAIDs) can injure the small
bowel as wells as upper gastrointestinal tract. Allison et al.(1)
reported that among 249 autopsied cases that used NSAIDs, small
intestinal injuries were found in 21 cases (8.4%), while among 464
cases that did not use NSAIDs, these injuries were found only in 3
cases (0.6%). However, details of this injurious effect of NSAIDs
had remained unclarified in the absence of high accuracy small
bowel testing methods. In the 21st century, introduction of new
modalities such as capsule endoscopy(2) and balloon endoscopy(3)
began to shed light on this “dark continent”, yielding findings such
as the potential of NSAIDs to induce small bowel injury frequently
regardless of the length of oral NSAID treatment period.
Furthermore, it has been demonstrated that 40–90% of NSAID
users had mucosal defects (erosion, ulcer, etc.) which could lead
to bleeding, perforation or stenosis.(4–7) Now, close attention is
paid to this condition. Although onset of NSAIDs-induced small
bowel mucosal injury is considered to involve many factors,(8–10)
its details remain unclarified. This paper will outline the signifi-
cance of mitochondrial disorders during onset of NSAIDs-induced
small bowel mucosal injury.
Mechanism for NSAIDs Induced Small Bowel Mucosal
Injury
NSAIDs, including low-dose aspirin, can induce diverse kinds
of mucosal injury such as redness, erosion and ulcer (Fig. 1),
affecting the entire small bowel. A mechanism of primary impor-
tance for onset of such injury is inhibition of cyclooxygenase
(COX) by NSAIDs and collapse of the mucosal defensive system
due to reduction of prostaglandin (PG) level following COX
inhibition.(11) Tanaka et al.(10) demonstrated that NSAIDs can
induce small intestinal damage when both COX-1 and COX-2 are
inhibited. Other than this mechanism, COX-independent topical
effect of NSAIDs on small bowel epithelium is considered to play
an important role in early processes of injury.(12) This direct
activity involves effects on mitochondria. That is, NSAIDs can
I
Fig. 1. NSAIDs induced small bowel injury. A, B: Capsule endoscope
pictures (low dose aspirin induced small bowel injury). C, D: Double 
balloon endoscope pictures (sulindac induced small bowel ulcer). A:
redness (arrow), B, C, D: ulcer.doi: 10.3164/jcbn.10 73
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injure epithelial cell mitochondrial function, inducing compromised
tight junction function, apoptosis, and necrosis.
As a result of such initial disorders, permeability across the
small bowel mucosa increases, facilitating invasion of small
bowel by luminal injury factors such as enterobacteria(13) and
bile.(14) Gram-negative bacteria having invaded the small bowel
mucosa activate toll-like receptor 4, a receptor for lipopoly-
saccharide, and induce excessive expression of cytokines such
as tumor necrosis factor-α through activation of the transcription
factors nuclear factor kappa B, leading to neutrophil infiltra-
tion.(15,16) Eventually, the small bowel which has weakened due to
PG deficiency cannot suppress stimulation by various injury
factors, possibly leading to formation of macroscopic ulcers. As
described above, injury of mitochondria by NSAIDs is a key event
which can induce a series of inflammatory reactions.
Mitochondrial Structure and Function
Mitochondrion is an organelle playing a central role in energy
production in organisms. There are about 100–2,000 mitochondria
in each cell. Structurally, the mitochondrion is surrounded by
double membranes (outer and inner membranes), and the inner
membrane partitions the central matrix from the intermembranous
space (the space between inner and outer membranes).(17) The
inner membrane of the mitochondrion has numerous folds called
“cristae”.
The mitochondrion takes up pyruvic acid, fatty acid, oxygen,
adenosine diphosphate (ADP) and phosphoric acid from the
surrounding cytoplasm. Within the mitochondrial matrix, pyruvic
acid and fatty acid are converted into acetyl CoA. Acetyl CoA then
enters the citric acid cycle and is degraded into nicotinamide
adenine dinucleotide (NADH) and carbon dioxide.
NADH is subsequently transferred into the inner membrane,
where it is converted into NAD, while donating electron to the
electron transport chain composed of three respiration enzyme
complexes (NADH dehydrogenase complex, cytochrome complex
and cytochrome oxidase complex). The electron transport chain
releases proton (H+) from the matrix to the intermembranous
space. As a result, there arises a pH and potential gradient between
the intermembranous space and the matrix. The energy derived
from this gradient is utilized by adenosine triphosphate (ATP)
synthetase to phosphorylate ADP and to synthesize ATP (oxida-
tive phosphorylation).(18) The electron transport chain is coupled
to oxidative phosphorylation. Uncoupling agents, which inhibit
this series of reactions, suppress the formation of ATP and induce
cell death such as apoptosis and necrosis.
NSAIDs Induced Small Bowel Injury and Mitochondrial
Disorders
Somasundaram et al.(19) observed the small bowel epithelium
following oral indomethacin treatment under an electron micro-
scope and reported morphological changes of the mitochondrion
in early processes of small bowel ulceration. They found
mitochondrial vacuolation 1 h after indomethacin treatment and
mitochondrial swelling and loss of cristae at 2 h. Similar morpho-
logical changes were noted also after treatment with dinitrophenol
(an uncoupling agent).
In a study in vitro, NSAIDs such as indomethacin, aspirin,
naproxen, and piroxicam uncoupled oxidative phosphorylation of
isolated rat liver mitochondria in micromolar and NSAIDs at
higher concentrations inhibited respiration in coupled mitochon-
dria,(19) suggesting that the changes in mitochondria observed
soon after indomethacin treatment are attributable to its activity
to uncouple oxidative phosphorylation and/or inhibit electron
transport. The above-mentioned morphological changes of mito-
chondria were reproduced also following non-oral treatment with
indomethacin, but they were absent in animals with ligated bile
duct. Aspirin exerted uncoupling activity in vitro but did not
induce morphological changes of mitochondria in epithelial cells
of the small intestine or small bowel ulceration when administered
orally.
When aspirin was administered directly into the small bowel,
severe mucosal injury was induced in the area distal to the site
of administration.(19) Considering that aspirin is immediately
absorbed in the stomach and duodenum without entering the
enterohepatic circulation and that indomethacin does not induce
ulcers in the bile duct-ligated rats,(14) these results strongly suggest
that mitochondrial disorders through the uncoupling of oxidative
phosphorylation and/or inhibition of respiration by NSAIDs are
indispensable for onset of small bowel ulcers, and it seems likely
that such topical effect of NSAIDs on small bowel epithelium is
dependent on local drug concentration (concentration within the
small bowel) and frequency of exposure to the drug. Other studies
also demonstrated importance of mitochondrial disorders by
NSAIDs on their intestinal toxicity.(20,21)
As described above, aspirin has been believed to be less harmful
to the small intestine for a long time. However, in 2007, Leung
et al.(22) reported a case of small intestinal ulcers in a patient taking
low-dose aspirin. So we evaluated ulcerogenicity of aspirin to
the small intestine. Capsule endoscopy identified red spots and
mucosal breaks (erosions/ulcers) in 100% (11/11) and 90.9%
(10/11) of patients who taking low-dose enteric-coated aspirin,
respectively.(5) One reason for this very high incidence of injuries
by low-dose enteric coated aspirin seems to be intensification
of mitochondrial disorders due to exposure of the small bowel
mucosa to high concentrations of aspirin dissolved within the
small bowel. Further studies including evaluation of the intestinal
toxicity of buffered aspirin are needed to support the hypothesis
that the enteric-coated formulation of aspirin might be a principal
cause of the damage.
Somasundaram et al.(23) conducted a detailed study on the role
of mitochondrial disorders in NSAIDs-induced small bowel
mucosal injury. They demonstrated: (1) uncombined treatment
with dinitrophenol elevated the permeability across small bowel
mucosa and induced relatively mild neutrophil infiltration,
although it did not induce ulceration; (2) non-oral treatment with
aspirin reduced the PG level in small bowel mucosa, but did
Table 1. Effects of drug administration routes on onset of small bowel ulcer
COX, cyclooxygenase.
Drugs and administration route COX inhibition Mitochondrial dysorders Ulceration
Oral treatment with indomethacin + + +
Non oral treatment with indomethacin + + +
Non oral indomethacin + bile duct ligation + – –
Oral treatment with aspirin + – –
Aspirin administration into small bowel + + +
Dinitrophenol administration into small bowel – + –
Non oral aspirin + dinitrophenol administration into small bowel + + + J. Clin. Biochem. Nutr. | March 2011 | vol. 48 | no. 2 | 119
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not affect small bowel permeability or induce ulceration; and (3)
treatment with dinitrophenol in combination with non-oral aspirin
resulted ulceration. These findings suggest that mitochondrial
disorders due to uncoupling of oxidative phosphorylation disturb
the mucosal barrier function and elevate the small bowel perme-
ability, but that PG deficiency through COX inhibition is addition-
ally needed for ulceration to occur (Table 1).
Mitochondrial Permeability Transition and NSAIDs
Mitochondrial permeability transition (elevation of permeability
across the mitochondrial membrane) is a phenomenon of sharp
elevation in the permeability of substances (below 1,500 Da in
molecular weight) across the mitochondrial membrane.(24) This
phenomenon is initiated by opening of the mega-channel called
mitochondrial permeability transition pore (PTP; composed of
voltage-dependent anion channel (porin), adenine nucleotide
translocase, cyclophilin D, etc.) on the mitochondrial membrane
(Fig. 2). When the PTP is opened, low-molecularweight substrates
can freely penetrate the mitochondrial matrix, carrying along
with them water and resulting in mitochondrial swelling and the
release of cytochrome c into the cytosol. Cytochrome c release
triggers a cascade of events that will lead to either apoptosis
(in ATP-replete cells) or necrosis (in ATPdepleted cells).(25–27)
As described above, NSAIDs have uncoupling activity. This
activity is considered to be attributable, at least partially, to induc-
tion of PTP. Masubuchi et al.(28) reported that diclofenac induced
mitochondrial swelling and depolarization of membranes, resulting
in release of Ca2+ (accumulated within mitochondria) and suppres-
sion of ATP formation by cells. They added that these effects of
diclofenac were suppressed by cyclosporine A (a PTP inhibitor).
Salicylic acid, an active metabolite of aspirin, was shown to open
PTP in kidney cells by Al-Nasser et al.(29) and in liver cells by
Trost et al.(30) On the basis of the findings from these studies, it is
now considered that the high cytotoxic activity of NSAIDs is
partially explained by their effect on PTP. So far as NSAIDs-
induced small bowel mucosal injury is concerned, opening of PTP
seems to be involved in elevation of the intestinal permeability,
epithelial cell apoptosis, and necrosis. The mechanism by NSAIDs
cause mitochondrial dysfunction is still unclear. Lal et al.(31)
reported that several NSAIDs including ketorolac and diclofenac
open PTP only under conditions of oxidative stress and in a Ca2+
dependent fashion.
Mitochondrial Disorders Due to Other Factors
Bile plays an important role in the mechanism for NSAIDs-
induced small bowel mucosal injury.(14,19) Bile acids such as
chenodeoxycholate are known to open PTP.(32) Furthermore, many
apoptotic signaling molecules act as PTP inducers, and these
include lipid mediators like ceramides and arachidonic acid.(33,34)
The latter is particularly interesting in the context of Ca2+-
dependent cell death. Indeed, it has been shown that arachidonic
acid-selective, Ca2+-dependent phospholipase A2 is essential for
the cytotoxic action of tumor necrosis factor-α,(35) which triggers
PTP opening(36,37) through activation of phospholipid hydrolysis(34)
and that arachidonic acid signals apoptosis(38,39) through a mito-
chondrial effect that can be amplified by inhibition of COX.(33) It
seems therefore likely that various factors other than NSAIDs are
also involved in mitochondrial disorders which arise during the
course of small bowel ulceration.
Rebamipide, an anti-ulcer agent,(40–42) suppressed indomethacin-
induced mitochondrial permeability transition in gastric epithelial
cells.(43) Recently, it was reported that this drug was useful in
preventing diclofenac-induced small bowel injury.(44) This finding
seems to be significant when arguing about the features of
NSAIDs-induced small bowel mucosal injury and drugs useful in
preventing or treating such injury.
Conclusions
Close attention has recently been paid to small bowel diseases
Fig. 2. Structure and function of mitochondrial permeability transition pore. HK, hexokinase; BR, benzodiazepine receptor; CK, creatinekinase;
ANT, adenine nucleotide translocase; VDAC, voltage dependent anion channel; CypD, cyclophilin D, OM, outer membrane; IM, inner membrane.doi: 10.3164/jcbn.10 73
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in the field of gastroenterology. NSAIDs-induced small bowel
injury is a representative of such small bowel diseases. The
mechanism for NSAIDs-induced small bowel injury involves
enterobacteria, bile, intestinal hypermotility, cytokines, neutro-
phils, etc. As described in this paper, mitochondrial disorders in
small bowel epithelial cells also play an important role in early
processes of this kind of injury. Although no valid means of
preventing or treating NSAIDs-induced small bowel injury has
been established, advances in mitochondrial studies may bring
about innovation in the prevention and treatment of this kind of
injury.
Abbreviations
ADP adenosine diphosphate
ATP adenosine triphosphate
COX cyclooxygenase
NADH nicotinamide adenine dinucleotide
NSAIDs non-steroidal anti-inflammatory drugs
PG prostaglandin
PTP permeability transition pore
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